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Thyroidcancerinchildrenandadolescentsisusuallyamajorconcernforphysicians,patients,andparents.Controversiesregarding
the aggressiveness of the clinical presentation and the ideal therapeutic approach remain among the scientiﬁc community. The
current recommendations and staging systems are based on data generated by studies in adults, and this might lead to overtreating
in some cases as well as undertreating in others. Understanding the diﬀerences in the biology, clinical course, and outcomes in
this population is crucial for therapeutic decisions. This paper evaluates the biology, clinical presentation, recurrences, and overall
survival as well as the staging systems in children and adolescents with diﬀerentiated thyroid cancer.
1.Introduction
Palpable thyroid nodules can be diagnosed in 4 to 7% of the
adult population. The high-resolution ultrasounds are able
todetectnodulesaround19%oftheadultpopulation,reach-
ing up to 67% in populations at higher risk such as women
and elderly individuals [1]. Considering autopsy series, this
prevalence can reach 50%. Although common, only 5% are
malignant [2].
Thyroid cancer is a rare pathology in childhood and ado-
lescence being responsible for 1.5–3% of all carcinomas in
this age group in the USA and Europe [3]. Such as the adults,
the diﬀerentiated thyroid carcinoma is the most commonly
found, especially the papillary carcinoma. In this popula-
tion, age, family history of thyroid disease and radiation
exposure are very important factors as already shown in
various ser-ies [4–6], especially after the Chernobyl accident,
when a substantial increase in the incidence of thyroid
carcinoma in children exposed to radiation was documented
[7].
Staging thyroid carcinoma in children and adolescents is
still a controversial issue. To avoid overtreating, a risk classi-
ﬁcation system, with the highest accuracy as possible, should
be used to identify patients who should be treated in a more
conservative or more aggressive way.
The current treatment recommendation is the total thyr-
oidectomy followed by radioiodine therapy, based on good
response and high disease-free survival rate for this age
group. However, many authors question the aggressiveness
of this treatment given the long lifespan of these patients and
long-term complications of high doses of radioiodine.
This revision aims to evaluate the initial therapeutic ap-
proach for children and adolescents with DTC regarding
surgery, adjuvant therapy, and staging.
2. Epidemiology of the Disease
The incidence of clinically palpable thyroid nodules in
childrenisestimatedtobearound1–1.5%.However,inteen-
agers, this prevalence may reach 13% [8]. When compared
to adults, children have four times greater risk of malignancy
when a thyroid nodule is diagnosed. In the US, around 350
individuals aged less than 20 years receive the diagnosis of
thyroid carcinoma annually [9]. In Brazil, the incidence can
reach 2% of all pediatric cancers according to the National
Cancer Institute database [10].2 Journal of Thyroid Research
Besides being a rare disease, the diﬀerentiated thyroid
carcinoma accounts for about 0.5–3% of all malignancies
in the pediatric population [8]. In addition, the thyroid is
one of the most common sites of a second primary tumor
in children who received external beam radiotherapy to the
neck for the treatment of other neoplasms.
The occurrence of thyroid carcinoma in early childhood
is very rare. In the literature, there are isolated cases of
diﬀerentiated thyroid carcinoma in neonates and infants
aged less than 1 year old [11, 12].
Furthermore, the incidence of thyroid cancer seems to
increase with age. In a series with 235 children and adoles-
cents who followed Maria Skłodowska Memorial Cancer
Center and Institute of Oncology for thyroid cancer, 5%
were diagnosed under 6 years old, 10% with 7–9 years,
increasing substantially after 10 years old. The diﬀerence
between boys and girls was seen more clearly after 13-14
years old [13]. Also the latest records of SEER cohort (Sur-
veillance, Epidemiology and End Results) from a group of
1753 patients aged less than 20 years conﬁrm the greater
incidence in girls (0.89 cases/100,000 for girls versus 0.2
cases/100,000 for boys) [14].
3. Risk Factors
In the past 60 years, the incidence of thyroid carcinoma in
the pediatric age group presented two distinct peaks. The
ﬁrst occurred around 1950 due to the use of radiation for the
treatment of common childhood conditions such as Tinea
capitis, acne, chronic tonsillitis, and thymus hyperplasia [15,
16]. In these cases, the thyroid carcinoma was diagnosed on
average 10–20 years after exposure, but with risk persisting
until 40 years later. When the causal relationship between
neckirradiationandthyroidcarcinomawasestablished,such
practices were abandoned leading to a decreasing incidence
inthispopulation[11]. These data led to acceptanceof ioniz-
ing radiation, a risk factor for the development of thyroid
cancer [17]. Similarly, external beam radiotherapy for the
treatment of other childhood malignancies would also be
associated with an increased incidence of thyroid carcinoma
in this population [18–20].
A second peak incidence occurred in the mid-1990s in
someregionsofEasternEuropeonbehalfofthenuclearacci-
dentthatoccurredinChernobylin1986[4–6].Theﬁrstcases
were diagnosed approximately 4-5 years later, especially in
children under 5 years old at the time of exposure [4, 21].
About 75% of these cases were exposed to the radioactive
fallout between birth and 14 years of age, with most of the
other 25% being from 14 to 17 years old at the time of ex-
posure [21]. The Chernobyl accident conﬁrmed the high-er
sensitivity of the pediatric population, to the eﬀects of radia-
tion when compared to adults [22].
The eﬀects of ionizing radiation on thyroid remain of
great interest of the scientiﬁc community. The British Child-
hood Cancer Survivor Study (BCCSS) is a cohort of 17,980
patients who were followed on average for 17.4 years, so far,
whose main objective is to determine the occurrence of a
second primary tumor. Eighty-eight percent of thyroid car-
cinomas were found in patients undergoing radiotherapy
covering the cervical region. The risk of thyroid carcinoma
was higher in patients treated for Hodgkin’s disease (RR
3.3—IC: 1.1–10.1) and non-Hodgkin Lymphoma (RR 3.4—
IC: 1.1–10.7) [23].
4. Presentationin Childhood
Regarding the clinical presentation, some characteristics are
markedly diﬀerent in pediatric population.
First,thetumorvolumetendstobelargerinpatientswith
less than 20 years old when compared to patients diagnosed
between 20 and 50 years [24]. Zimmerman et al. already
showed, in 1988 [25], that newly diagnosed tumors were
greater than 4cm in 36% of children as opposed to 15% of
adults and had less than 1cm in 9% of children as opposed
to 22% of adults. In series contemplating only patients with
papillary carcinoma, only 1.5–3% of tumors had less than
1cm size at diagnosis [26, 27].
Furthermore, probably due to the fact that thyroid vol-
ume is smaller in children, an early involvement of thyroid
capule and surrounding tissue is seen [28]. Thus, the cate-
gory of microcarcinoma (including tumors with less than
1cm), commonly used in adults, should be avoided in child-
ren, since a 1cm tumor constitutes a very important ﬁnding
in this age group.
Secondly, the multicentricity also occurs more frequently
in the pediatric age group, especially in the subtype papillary
carcinoma [29, 30]. Such outbreaks have been considered as
polyclonal in most cases [31]. This becomes especially im-
portant as it can be used as an argument in favor of total
thyroidectomy as primary surgical approach for these pa-
tients.
Third, pediatric patients have a higher probability of cer-
vical lymph node metastasis as well as distant metastasis
[21, 32]. In a series done at the Mayo Clinic with 1039
patients with papillary thyroid carcinoma, cervical lymph
node invol-vement was detected in 90% and metastasis
distance in approximately 7% of children versus 35%
of cervical lymph node involvement and 2% of distance
metastasis in adults [25]. In a study performed by our
group with 65 children and adolescents, the occurrence
lymphnodemetastasisatdiagnosiswas61.5%,localinvasion
39.5%, and distant metastases 29.2%, all of them being
in the lungs [33]. As the diagnostic methods improved,
clinical presentation of diﬀerentiated thyroid carcinoma in
the pediatric age group has changed over time. A review held
at the University of Michigan comparing patients diagnosed
between 1936–1970 with those diagnosed between 1971
and 1990 showed that the patients diagnosed more recently
had a lower in-cidence of lymph node involvement (36%
versus 63%), less local invasion (6% versus 31%), and lower
incidence of lung metastases (6% versus 19%), reﬂecting a
precocity in diagnosis over the decades, with a consequent
better pro-gnosis, particularly if older than 10 years of age
[34].
The most common site of distant metastasis in children
is the lung with just a few cases described of bone metastases
[12, 35] and of central nervous system metastases [12, 36].Journal of Thyroid Research 3
The histological subtype follows a distribution similar to
adults: 90–95% papillary carcinomas and 5% follicular [9,
37,38].Poorlydiﬀerentiatedtumorsasinsularandanaplastic
are extremely rare [38].
5. Prevalence of Mutationsand
Expression of NIS
An important diﬀerence between thyroid carcinoma in
pediatric and adult age is related to the high prevalence of
expression of sodium-iodide transporter (NIS) in metastatic
focus found in children [39–41]. In the absence of stimula-
tion of TSH, the expression of NIS is undetectable in 65% of
papillary tumors and 56% of follicular in patients with less
than20years[39].Incontrast,theexpressionofNISisabsent
or negligible in 90% of diﬀerentiated carcinomas in adults,
either when searched by PCR with reverse transcription [40]
or by Immunohistochemistry [42].
The greater expression of NIS in the pediatric population
results in greater responsiveness to radioiodine treatment
and better prognosis. In young patients, the recurrence risk
increases in those who do not express the protein NIS when
compared to those who have it [39]. Thus, the degree of NIS
expression correlates with radioiodine avidity by metastases
[43] and lower clinical recurrence rates [44].
Regarding the molecular biology of these tumors, ap-
parently RET-PTC rearrangements occur in childhood more
frequently than in adults, especially in the radiation-relat-
ed tumors. Initial studies of Chernobyl-associated PTC
identiﬁed RET/PTC-3 as the most common form of RET
rearrangement in radiation-induced childhood PTC [45–
49]. However, Pisarchik et al. found that 29% of adult and
childhood PTC in Belarus actually contained RET/PTC-1 re-
arrangements [45]. It was hypothesized that the increase in
frequency of the RET/PTC-1 rearrangements in those adults
could be related to a longer latency period in those cases. In
addition, patients whohad RET/PTC-3rearrangementswere
diagnosed much earlier after the Chernobyl incident [45].
Motomura et al. reported that 71% of sporadic PTC from
children in the United States and 87% of PTC from child-
renlivinginradiation-contaminatedareasofBelaruscontain
rearrangements of the RET oncogene [50, 51].
Besides RET/PTC rearrangements, other groups suggest-
ed the immunohistochemical overexpression of MET associ-
ated with high recurrence rate in children and adolescents
[51], in addition to the immunohistochemical overexpres-
sionofgrowthfactorsofvascularendothelium [52]andtelo-
merase, however, without deﬁnitive ﬁndings [53].
In the case of follicular carcinomas, the two most freq-
uently involved genes would be RAS and PPAR gamma,
and their rearrangement might serve as a trigger to the
transformation from adenoma to carcinoma [54]. However,
little is known about its role in the prognosis of such neo-
plasms.
6.Prognosis
The prognosis of these tumors in childhood is a very in-
teresting issue. Despite having a greater recurrence rate
when compared to adults, survival seems to be better [55].
Mazzaferri and Kloos in a series with 16.6 years of followup,
found a recurrence rate, in patients with less than 20 years
old, around 40%, while those with more than 20 years of age
had 20% recurrence rates [24]. In contrast, survival is greater
than in adults. In a study done in Minsk with a large cohort
of 741 patients, the survival rate was 99.3% in 5 years and
98.5% in 10 years in a pediatric population [56].
Age seems to be a very important prognostic factor in
thyroid cancer. Children and adolescents are usually classi-
ﬁed as having a better prognosis and they are classiﬁed to-
gether with all patients under 45 years old. However, Lazar
et al. showed that patients with less than 10 years, mainly
prepubertal, had a worse prognosis than the older and more
advanced pubertal stages patients [34].
7. Treatment
Regardless, the biology of papillary and follicular tumors,
the therapeutic approach is very similar for both subtypes
of tumors [12, 55]. As well as in adults, the treatment of
diﬀerentiatedthyroidcarcinomaisbasedonthecombination
of three therapeutic modalities: surgery, hormone replace-
ment with levothyroxine, and radioiodine treatment. The
surgery can vary from lobectomy to total thyroidectomy
accompanied by cervical lymphadenectomy in various ways.
Latest guidelines recommend total thyroidectomy, mainly
for larger tumors, 1cm [24, 57, 58] associated with cervical
dissection of central or lateral compartment block if lymph
node metastases are seen in preoperative imaging or during
the surgery. The main surgical complications include persis-
tent hypoparathyroidism and laryngeal nerve damage that
may cause a wide spectrum of clinical consequences: from
hoarseness to total vocal cord paralysis, with need for de-
ﬁnitive tracheotomy [59].
After a total or near-total thyroidectomy, the volume of
remaining gland should be less than 2g seen in the cervical
ultrasound performed around one month after surgery [55].
Even after total thyroidectomy, some radioiodine uptake
is seen in the thyroid bed. Generally, this phenomenon is
assigned to the remaining normal thyroid cells left by the
surgeon to protect the nerve and around Berry’s ligament.
However, because multicentricity and metastatic disease are
more common in the pediatric age group, the possibility of
such outbreaks being malignant cells cannot be ruled out.
Thus, most societies recommend radioiodine ablation in the
vastmajority of patients under 45 yearsold butnone of them
make speciﬁc recommendations for children and adolescents
[55, 58–60]. However, the radioiodine treatment should be
used to complement, not replace, the total thyroidectomy.
The success of ablation is signiﬁcantly lower in patients who
have undergone less extensive surgery, such as near-total
thyroidectomy [24, 61]. In most cases, one dose of radio-
iodine treatment is capable of achieving complete ablation;
however, the procedure may have to be repeated usually
6–12 months after the ﬁrst [62]. Some variables seem to
inﬂuence the success of thyroid remnant ablation and the
most important one seems to be the presence of lymph node
metastases in low risk patients [33]. However, little is known4 Journal of Thyroid Research
about the prognostic signiﬁcance of achieving a successful
ablation with the ﬁrst dosage of I-131 in patients with diﬀer-
entiated thyroid cancer. Mazzaferri and Jhiang have shown
that adult patients with a successful ablation had a better
prognosis than those who failed: disease-free survival was
87% versus 49% after 10 years; additionally, thyroid-cancer
relatedsurvivalwas93%versus78%[63].Ontheotherhand,
the Mayo Clinic studies did not show a major impact in the
overall survival and in the recurrence rates [25, 64].
The third treatment modality is thyroid hormone re-
placement.Thissuppressivetherapywiththyroidhormoneis
believed to reduce the risk of growth or tumor proliferation
inducedbyTSH[65].Inchildrenandadolescentsstillunder-
going growth, there are several studies that guarantee the
eﬃcacy and safety of this approach, particularly with regard
to their ﬁnal height, as long as they are carefully controlled
[55].
Possible side eﬀects of long-term suppressive therapy in-
clude osteoporosis and cardiovascular disease, especially of
left ventricular hypertrophy [65, 66]; such are eﬀects docu-
mented in adults.
8. RadioiodineinChildhoodandItsSideEffects
The radioiodine treatment in pediatric age should be pre-
ferably administered in capsule form, in association with an
antiemeticmedication,inanattempttoensurethattheactiv-
ity administered has been fully ingested.
Iodine 131 therapy can lead to a temporary loss of sali-
vary ﬂow and change of taste in up to 30% of the cases [59].
However, permanent xerostomia is rare. The most serious
side eﬀect from radioiodine treatment is radiation-induced
leukemia that happen in 1 out of 26 treated patients in a
studyheldinNetherlandswithchildrenandadolescents[59].
Another concern is pulmonary ﬁbrosis that may occur in up
to 1% of cases, mostly in those with diﬀuse lung metastases.
Both eﬀects are dose dependent and usually are seen in pa-
tients that underwent multiple treatments with a total dose
above 600mCi [59].
The actinic sialoadenitis is common but usually is rever-
sible [67]. This complication is more frequent in the absen-
ce of iodine-avid metastases and discrete thyroid remnant,
situations with greater availability of radioiodine to the sali-
vary glands [34, 67]. A transitional impairment of sper-
matogenesis [34, 67, 68] is observed after ablation thera-py
with high doses of iodine 131. Permanent infertility is pos-
sible with accumulated high doses [69]. Usually the pro-
duction of testosterone is preserved [68, 69], although an
elevation of LH can occur [69]. In women, an increment of
FSH and reversible menstrual changes [68, 69] and even in-
fertilityandearlymenopause[69]mayoccurafterhighdoses
of radioiodine.
Whereas the maximum dose absorbed by the gonads is
5mGy/mCi, Maxon inferred that permanent infertility does
not occur in women with doses up to 300mCi iodine-131
a n dh a p p e ni nl e s st h a n1 0 %o fm e nw i t ht h i ss a m ed o s e .
With doses of 800mCi or more, infertility would go up to
60% of women and more than 90% of men [69, 70].
In adolescent boys, radioiodine can also cause a decrease
in quantity and aﬀect sperm quality leading to infertility that
may be transient or permanent [71].
9. Controversies
Even with all knowledge acquired today, the controversies on
the ideal approach of these patients remain. The lack of stud-
ies demonstrating real beneﬁt in overall survival of these pa-
tients comparing the diﬀerent therapeutic modalities con-
tributestothisdiscussion.GroupsliketheMayoClinicadvo-
cate a conservative treatment (considering the possibility of
partialthyroidectomywithoutadjuvantradioiodinetherapy)
using as argument the observation of 1.7% mortality after
28 years of monitoring and 3.4% recurrence in 30 years in
58 patients under 17 years at diagnosis, in which only 38%
underwent total thyroidectomy and 17% radioiodine treat-
ment adjuvant, that is, a good evolution even without the
traditionally recommended intensive treatment [25].
The main arguments of those who prefer a more aggres-
sive approach are based on studies with long follow-up per-
iod analyzing disease-free survival and recurrence rate. For
example, Chow et al., in this univariate analysis, showed that
thelocalrecurrencerateinchildrenwasreducedfrom42%to
6.3% when radioiodine adjuvant treatment was per-formed
(P = .0001) [72].
The application of the current staging system created by
the International Union against Cancer (AJCC/UICC) bas-
ed on the TNM and age is recommended for all types of
tumors including thyroid [73], in an attempt to standardize
the tumoral extension description [73]. However, in thyroid
carcinoma, TNM staging does not take into consideration
several additional factors that inﬂuence the evolution and
prognosis and so has a limited capacity of predicting out-
come in some cases. Thus, several other staging systems are
being proposed in the attempt to achieve a better accur-
acy, among them: CAEORTC, AGES, AMES, MACE, and
ATA. [58, 74–77]. These systems take into account factors
identiﬁed as predictor of outcomes in retrospective studies,
usually taking into consideration the presence of metastases,
the age of the patient, and the extent of the tumor site.
However, most of them were developed to predict cancer-
speciﬁc mortality not to predict recurrence [76]. Because the
mortality is low, there is not an ideal standing system for
thyroid cancer yet, especially when it comes to the pediatric
population. These patients are usually grouped with minors
45 years which may be responsible for the low accuracy
of all existing systems for patients under 20 years of age,
that clearly have a diﬀerent clinical presentations and bio-
logy when compared to older patients. In a recent study
performed with 65 patients under 20 years old, the staging
system proposed by ATA in 2009 seems to be better than the
others for predicting disease-free survival [33]. More studies
with this speciﬁc population are needed to develop a speciﬁc
risk assessment for this age group.
10. Conclusion
Although children with DTC typically present with locore-
gional metastases and a high rate of distant metastaticJournal of Thyroid Research 5
disease, overall survival is very good. Treatment should be
based on their increased risk for recurrence instead of overall
mortality, and lifelong followup is required because recur-
rence and death may not occur for decades after diagnosis.
Initial treatment will generally include total thyroidectomy
and centralcompartment lymph node dissection especiallyif
lymph node disease is found in the preoperative evaluation.
Radioiodine ablation should be individualized and given to
those with a higher risk of recurrence.
Large multicenter studies are needed to better under-
stand optimal treatment approaches to this unique pop-
ulation. All care of pediatric DTC should be delivered
by multidisciplinary specialized teams which include both
pediatricians and thyroid cancer specialists to minimize
possible complications and ensure competent followup.
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